Correlation of Coagulation Markers and 4F-PCC-Mediated Reversal of Rivaroxaban in a Rabbit Model of Acute Bleeding
Open Access
- 1 March 2015
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 135 (3) , 554-560
Abstract
No abstract availableKeywords
Funding Information
- CSL Behring
This publication has 38 references indexed in Scilit:
- Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human BloodPLOS ONE, 2013
- Managing Bleeding in Anticoagulated Patients in the Emergency Care SettingThe Journal of Emergency Medicine, 2013
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With RivaroxabanStroke, 2013
- Oral Anticoagulant TherapyChest, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysJournal of Thrombosis and Haemostasis, 2011
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitorThrombosis Research, 1995